Atlas Link Technology Co., Ltd.

Atlas Link Technology Co., Ltd. specializes in in vitro diagnostic (IVD) devices designed for self-testing at home. Their product range includes urine pregnancy tests (detecting human chorionic gonadotropin, or hCG) in three formats—strip, cassette, and midstream—along with a fecal occult blood test and urine tests for luteinizing hormone (LH). These devices are intended for individual use without professional medical supervision, enabling users to perform tests in private settings.

Atlas Link Technology Co., Ltd. is headquartered in China. Since their devices are classified as Class II in vitro diagnostics (IVDs), they must comply with both domestic Chinese regulations and international standards if marketed abroad. The company’s devices are registered in the EU’s EUDAMED database and the FDA’s 510(k) premarket notification system, indicating they undergo evaluation for compliance with European and U.S. regulatory requirements before commercialization in those markets.

Atlas Link Technology Co., Ltd.’s devices are classified as Class II in vitro diagnostics (IVDs). This classification is determined by their intended use—self-testing for conditions like pregnancy or occult blood—where moderate risk exists if misused or incorrectly interpreted. Class II devices require stricter regulatory scrutiny than lower-risk Class I devices but do not carry the highest risk (Class III). The classification influences testing requirements, labeling obligations, and post-market surveillance, ensuring they meet safety and performance standards before reaching consumers.

Atlas Link Technology Co., Ltd.’s devices are listed in EUDAMED (the European Union’s medical device registry) and the FDA’s 510(k) database (for U.S. premarket notifications). A listing in EUDAMED confirms the devices have been authorized for sale in the European Economic Area under EU IVD Regulation (IVDR) requirements. The FDA 510(k) listing indicates these devices have undergone a premarket review to demonstrate substantial equivalence to a legally marketed predicate device in the U.S., ensuring compliance with FDA regulations before commercial distribution.